FY2027 EPS Estimates for Roche Cut by Erste Group Bank

Roche Holding AG (OTCMKTS:RHHBY) – Erste Group Bank lowered their FY2027 earnings per share estimates for Roche in a research note issued on Wednesday, March 4th. Erste Group Bank analyst H. Engel now expects that the company will earn $3.48 per share for the year, down from their previous estimate of $3.50. The consensus estimate for Roche’s current full-year earnings is $2.81 per share.

Other research analysts have also issued research reports about the stock. Citigroup started coverage on shares of Roche in a research note on Tuesday, January 27th. They set a “buy” rating for the company. Deutsche Bank Aktiengesellschaft upgraded shares of Roche from a “sell” rating to a “hold” rating in a report on Tuesday, November 11th. Wolfe Research restated an “outperform” rating on shares of Roche in a research note on Thursday, February 26th. Barclays upgraded Roche from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, January 6th. Finally, HSBC reiterated a “buy” rating and issued a $57.00 price objective on shares of Roche in a report on Wednesday, December 10th. Four equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $57.00.

Roche Trading Up 2.2%

Shares of Roche stock opened at $55.39 on Monday. The business’s fifty day simple moving average is $55.93 and its 200-day simple moving average is $48.69. The company has a quick ratio of 1.12, a current ratio of 1.38 and a debt-to-equity ratio of 0.72. Roche has a 52 week low of $34.75 and a 52 week high of $60.85.

Institutional Trading of Roche

Institutional investors have recently bought and sold shares of the business. IHT Wealth Management LLC purchased a new stake in Roche during the fourth quarter worth approximately $400,000. Atlas Capital Advisors Inc. acquired a new stake in Roche during the 4th quarter worth $192,000. Sarver Vrooman Wealth Advisors purchased a new stake in Roche in the fourth quarter valued at $287,000. Hantz Financial Services Inc. boosted its stake in Roche by 164.9% in the fourth quarter. Hantz Financial Services Inc. now owns 79,732 shares of the company’s stock valued at $4,112,000 after acquiring an additional 49,633 shares in the last quarter. Finally, PNC Financial Services Group Inc. grew its holdings in shares of Roche by 18.4% during the fourth quarter. PNC Financial Services Group Inc. now owns 22,255 shares of the company’s stock worth $1,148,000 after purchasing an additional 3,456 shares during the last quarter.

About Roche

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.